Kornimate/medical-research-clean huggingface dataset:
a clinical study on the safety and efficacy of gp681 tablets in the treatment of uncomplicated acute influenza

Conditions: Influenza

Summary: analyse the time of flu symptom relief in adults with uncomplicated acute influenza,to evaluate the antiviral effects of high and low doses of gp681 tablets, and explore the optimal dose for phase iii clinical trials.


Eligibility criteria:
inclusion criteria: * positive influenza rapid antigen test; * fever (axillary temperature ≥37.3℃) or the axillary temperature ≥37.3℃ after taking the medicine for more than 4 hours; * at least one systemic symptom and respiratory symptom related to a moderate or above influenza virus infection: 1. systemic symptoms: headache, fever or chills, muscle or joint aches, fatigue; 2. respiratory system symptoms: cough, sore throat, nasal congestion. * time of disease symptoms ≤48h exclusion criteria: * diagnosed as severe influenza patient ; * known history of dysphagia or any gastrointestinal disease that affects drug absorption (including but not limited to reflux esophagitis, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, stomach after subtotal resection, etc.); * have used anti-influenza virus drugs (oseltamivir, zanamivir, peramivir, favipiravir, abidol, baloxavir dipivoxil, amantadine, or diamond) within 2 weeks before screening ethylamine, etc.); * acute respiratory infections, otitis media, sinusitis or other infectious diseases such as bronchitis, pneumonia, tuberculosis, etc. occurred within 2 weeks before screening, and are in the acute stage; * patients who also suffer from bacterial or viral infections and need systemic antibacterial or antiviral therapy
to exam the effects of phyllanthus niruri extracts on human neutrophils

Conditions: Neutrophil; Phyllanthus Abnormis Poisoning

Summary: to exam the effects of phyllanthus niruri extracts(corilagin, phyllanthin and brevifolin) on human neutrophils

phyllanthus niruri extracts have anti-inflammatory effects in various cellular systems (monocytes, neutrophil). however, the underlying effects and mechanisms of phyllanthus niruri extracts on neutrophils have not yet been investigated in detail. in this study, first we would like to systemic exam the effects of corilagin, phyllanthin and brevifolin, three major active components, on human neutrophils. further to clarify whether phyllanthus niruri extracts have any effect on neutrophils that may provide some insights on the ability of these compounds to modulate the innate immune response in acute organ injury.

Eligibility criteria:
inclusion criteria: * healthy volunteers who aged 20-35 years. * do not have coagulopathy, systemic infection disease and severe liver and renal function impairment * accept venipuncture exclusion criteria: * healthy volunteers who aged over 35 years. * have coagulopathy, systemic infection disease and severe liver and renal function impairment
red light childhood myopia proof-of-concept

Conditions: Myopia

Summary: in this project the research team will begin to find out whether shining a red led light at the eyes can slow down the worsening of short-sightedness in children. this is important, because short-sightedness now starts at a younger age and worsens faster than in the past. many people are at risk of permanently losing their eyesight in middle-age because of short-sightedness. the researchers plan to use red led light, which is safe to use. red-light treatment improves the blood flow at the back of the eye, in a layer called "choroid", which can be measured on eye-scans. the team have done a study with healthy adults, which showed that red-light is safe and gently improves the blood flow at the back of the eye. in adults, this has no effect on myopia, because their eyes are fully grown. in children, red-light may slow down myopia, and in this project, the researchers want to find out which level of red-light is needed to have this effect. the researchers will ask 24 children age 5-12 years to use red-light for three minutes twice a day for three months. three will be 4 groups of children, and each group will use a different level of brightness. the researchers will measure the eye length and the thickness of the choroid at the start and 1 and 3 months later and compare the change in eye length between the different groups. in practice, children will need to use the treatment for several years. the researchers will use the results of this study to prepare a longer study with more children.


Eligibility criteria:
inclusion criteria: * short-sightedness between -1.00d and -6.00 diopters in both eyes * best-corrected visual acuity 0.1 logmar or better in both eyes exclusion criteria: * underlying condition/syndrome causing myopia * previous or current myopia-modifying treatment * abnormal ocular refractive anatomy or previous intraocular or ocular surgery
trans-cutaneous vagal nerve electrical stimulation and irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: this pilot study plan to investigate the sympathovagal balance in women affected by irritable bowel syndrome (ibs), and to evaluate the effect of 6 months of trans-cutaneous vagal nerve electrical stimulation on digestive physiology (intestinal transit time, intestinal mucosal permeability, systemic and local inflammation), symptoms and quality of life. the safety of the electrical stimulation of the left vagal nerve will also be evaluated. ten women, age between 18 and 60, will be included.


Eligibility criteria:
inclusion criteria: * women aged 18-60, * clinical rome iii criteria for ibs exclusion criteria: * pregnancy, * low intensity symptoms (francis score between 75-150) * ibd, coeliac disease * past history of abdominal surgery (appendectomy and cholecystectomy allowed) * chronic use of analgesics, anti-depressants

Keywords: irritable bowel syndrome vagal nerve stimulation quality of life
effects of extracorporeal shock wave therapy and pulse electromagnetic field therapy on lymphoedema

Conditions: Lymphedema

Summary: lymphedema occurs not only in patients with breast cancer and gynecological cancers but also in those where lymphatic drainage is obstructed. accumulation of lymphatic fluid within tissues results in limb swelling. additionally, proteins present in lymphatic fluid might lead to fibrosis within tissues, causing various challenges for patients. the changes in volume and weight can significantly impact daily life activities such as eating, brushing teeth, and other routine tasks. furthermore, it can lead to clothing difficulties and provoke unwanted attention due to aesthetic concerns. currently, there is no definitive treatment for lymphedema. however, prospective research has shown promising results in applying extracorporeal shock wave therapy (eswt), originally used for musculoskeletal disorders like plantar fasciitis, tennis elbow, frozen shoulder, and non-union fractures, to lymphedema patients. similarly, pulse electromagnetic field therapy (pemft), widely used for pain management and muscle strengthening, has the potential for treating lymphedema as it can enhance blood circulation and stimulate muscle contractions. this research project aims to explore the effectiveness and sustainability of using eswt and pemft for lymphedema patients. by applying these therapies to lymphedema patients, this study aims to evaluate their treatment outcomes and long-term effects.

there is currently no cure for lymphedema. literature review revealed extracorporeal shock wave therapy (previously applied to soft tissue diseases such as plantar fasciitis, tennis elbow, frozen shoulders, and poor fracture healing) showed positive therapeutic effect for patients with lymphedema. another widely used therapy for pain treatment and muscle strengthening is pulse electromagnetic field therapy (pemft), which has the potential to be used in the treatment of lymphedema due to its ability to increase blood circulation and stimulate muscle contractions. this study design to evaluate the effect of extracorporeal shock wave therapy on patients with lymphedema, and further explore its therapeutic effect.

Eligibility criteria:
inclusion criteria: * participants must be at least 20 years old and have no significant cognitive, language comprehension, or communication issues, be able to understand and follow instructions, and sign the informed consent form. * individuals with lymphedema after treatment for breast cancer or gynecologic cancer are eligible (lymphedema is defined as a circumference difference of \>2 cm in the same location on both limbs). * you must be able to attend follow-up appointments at specific times during the 12 months of the trial, referred by a rehabilitation physician in the outpatient department. exclusion criteria: * the affected limb has unhealed open wounds, acute infections, or other conditions unsuitable for contact-based treatment. * the affected limb has metastatic tumors. * the affected limb has untreated deep vein thrombosis. * severe clotting abnormalities.
study of viramidine to ribavirin in patients with chronic hepatitis c who are treatment-naive

Conditions: Chronic Hepatitis C

Summary: this purpose of this study is to determine the safety and effectiveness of viramidine to ribavirin in chronic hepatitis c patients who have never before recieved treatment.

compare the efficacy and safety of viramidine 600 mg bid versus ribavirin 1000/1200 mg/day, both drugs administered in combination with pegylated interferon alfa-2b to treatment-naive patients with chronic hepatitis c (chc)

Eligibility criteria:
inclusion criteria: * treatment-naive patients with compensated chronic hepatitis c. * hcv rna \>2000 copies/ml (780 iu/ml) as determined by ngi superquant serum hcv rna quantification, with a lower limit of detection of 100 copies/ml (39 iu/ml). exclusion criteria: * severe neuropsychiatric disorders * history or clinical manifestations of significant metabolic, hematological, pulmonary, ischemic heart disease, significant or unstable heart disease, gastrointestinal, neurological, renal, urological, endocrine, opthalmologic disorders including severe retinopathy, or immune mediated disease * pregnant or breast-feeding patients

Keywords: viramidine ribavirin valeant hepatitis c pegylated interferon alfa-2b
intravenous rpr109881 in male or female patients with advanced breast cancer who no longer respond to anthracycline, taxane and capecitabine treatment

Conditions: Breast Cancer

Summary: the purpose of this clinical trial is to determine if the investigational drug is able to reduce/shrink advanced breast cancer tumors in patients who no longer benefit from anthracyclines, taxanes and capecitabine.

all patients in this trial will receive the investigational (chemotherapy) drug at an optimal dose as determined by previous clinical trials. the investigational drug is given through a vein once every three weeks. this drug prevents tumor cells from dividing, so they may stop growing or die.

Eligibility criteria:
inclusion criteria: in order to be eligible for this trial you must: * have a diagnosis of breast cancer that is now metastatic (meaning the cancer has spread beyond its original location) or a recurrence of the cancer in its original location that cannot be removed by surgery. * have received previous treatment with anthracyclines (e.g. doxorubicin \[adriamycin or doxil\] or epirubicin \[ellence\]), taxanes (paclitaxel \[taxol or abraxane\] or docetaxel \[taxotere\]) and capecitabine (e.g. xeloda) for your breast cancer and your doctor has determined that these treatments are no longer of benefit to you. * be at least 18 years of age * not be taking other treatments for your cancer at the time you enter the trial. * not be pregnant * additionally, there are other criteria for study entry that a doctor participating in this study will need to review in detail with you and clinical assessments may need to be performed (lab tests, ct scans). exclusion criteria: * none listed here. can be discussed with your doctor.

Keywords: metastatic breast cancer
pregabalin epilepsy add-on trial

Conditions: Partial Seizures

Summary: to evaluate the efficacy of pregabalin as adjunctive therapy, using a flexible, optimized dose schedule with dose adjustment based on clinical response and tolerability, compared to placebo in subjects with partial seizures


Eligibility criteria:
inclusion criteria: * have a diagnosis of epilepsy with partial seizures (as defined in the ilae classification of seizures) and be currently taking 1-3 aeds * have a minimum of 4 partial seizures occurring over at least 2 days during the 6-week baseline with no 28-day period free of partial seizures exclusion criteria: * have a treatable cause of seizures * are currently receiving treatment with cns-active compounds (exception: single antidepressant, hypnotics, and standard aeds), vigabatrin, felbatol (felbamate), neurontin (gabapentin)
gastroprotective agent compliance in patients at risk suffering from a gastrointestinal(gi) ulcer

Conditions: Gastrointestinal Hemorrhage; Ulcer

Summary: the purpose of this study is to assess gastroprotective agent compliance in patients at risk suffering from a gastrointestinal bleeding ulcer or a symptomatic ulcer with nsaid.


Eligibility criteria:
inclusion criteria: * patients at risk suffering from a gastrointestinal bleeding ulcer or a symptomatic ulcer confirmed by endoscopy

Keywords: compliance, france gastrointestinal bleeding ulcer or symptomatic ulcer with nsaid
miromatrix biological mesh for ventral hernia repair

Conditions: Ventral Hernia

Summary: this study is being conducted to gather long-term data of the performance of the miromatrix biological mesh.

miromatrix medical inc. has developed a new biologic mesh, called miromesh®. miromesh received fda 510(k) clearance with an indication for reinforcement of soft tissue on march 31, 2014 under k134033. miromatrix biologic mesh is a non cross-linked, acellular surgical mesh that is derived from the highly vascularized porcine liver. this study will serve to provide clinicians with high-quality clinical data in order to provide them with a higher degree of confidence when selecting miromesh for ventral hernia repair.

Eligibility criteria:
inclusion criteria: * between 18 and 80 years old on the day of study enrollment * ventral or incisional hernia greater than 9 cm2 for which the physician anticipates ability to achieve midline fascia closure following a retro-rectus repair/component separation * hernia classified as cdc class 1 or 2 preoperatively * able and willing to sign the consent form and comply with all study visits and procedures * commit to non-smoking for at least 4 weeks prior to procedure exclusion criteria: * sensitivity to porcine material * scheduled for a concomitant procedure of a wound classified as other than clean * immunocompromised or at risk of immunosuppression (i.e. be hiv positive, be experiencing organ rejection, be a recent or anticipated chemotherapy recipient) as determined by the investigator * bmi ≥40 * a1c level ≥10.0 * participating in another clinical study * cirrhosis, and/or ascites * diagnosed with a collagen vascular disorder * american society of anesthesiology (asa) class 4 or 5 * allergic to tetracycline or kanacmycin * life expectancy of less than 2 years at the time of enrollment * any condition in the opinion of the investigator that would preclude the use of the study device, or preclude the subject from completing the follow-up requirements
first crush: piloting the preliminary feasibility and acceptability of the competence in romance and understanding sexual health (crush) curriculum

Conditions: Autism; Autism Spectrum Disorder

Summary: the goal of this clinical trial is to learn about the feasibility and acceptability of a behavioral intervention in designed to provide sexual education and improve the behavioral skills of autistic adults for intimate relationships. the main questions it aims to answer are: * acquire feasibility and acceptability data for delivery of the crush curriculum in a group didactic setting plus 1-1 coaching. * acquire feasibility and acceptability data regarding the assessment battery for future clinical trials. participants will complete: * a screening call. * provide documentation of a diagnosis of autism spectrum disorder. * 3 visits to assess knowledge and behaviors related to dating and sexual health at each point throughout the training curriculum (before beginning, midway, and after finishing). * 15-20 training sessions to participate in the crush curriculum. after each session, provide feedback about the session.

the goal of this clinical trial is to learn about the feasibility and acceptability of a behavioral intervention in designed to provide sexual education and improve the behavioral skills of autistic adults for intimate relationships, called crush. the main questions it aims to answer are: * acquire feasibility and acceptability data for delivery of the crush curriculum in a group didactic setting plus 1-1 coaching. * acquire feasibility and acceptability data regarding the assessment battery for future clinical trials. participants will complete: * a screening call. * provide documentation of a diagnosis of autism spectrum disorder. * 3 visits to assess knowledge and behaviors related to dating and sexual health at each point throughout the training curriculum (before beginning, midway, and after finishing). * 15-20 training sessions to participate in the crush curriculum. after each session, provide feedback about the session.

Eligibility criteria:
inclusion criteria: * 18 to 30 years old; * documentation of a prior diagnosis of autism spectrum disorder (asd) or receipt of services based on an asd diagnosis; * ability to provide consent for the protocol and understand task demands (i.e., approximately wasi-2 full scale iq of 70 or above); * fluent in english exclusion criteria: * non-english-speaking participants (less than 50% of speech in english); * known genetic etiology of asd (e.g., fragile x); * major mental illness (e.g., bipolar disorder, schizophrenia, or psychosis). * live more than 35 miles from two brookline place, brookline, ma where intervention sessions will be offered.
ambulatory adaptation to non-invasive mechanical ventilation

Conditions: Chronic Respiratory Failure

Summary: a randomised study to assess the effectiveness of ambulatory adaptation to non-invasive mechanical ventilation in patient with hypercapnic respiratory failure secondary to neuromuscular diseases or alterations in thoracic cage in comparison with hospital adaptation.


Eligibility criteria:
inclusion criteria: 1. age between 18 and 75 2. chronic respiratory insufficiency secondary to neuromuscular disease or thoracic cage alterations with indication of non-invasive mechanical ventilation (presence of fatigue, dyspnea, morning headache, etc) plus one of the following criteria): * paco2 \> 45 mmhg * night time oxygen saturation \< 88% at least for 5 consecutive minutes * in neuromuscular diseases, pim \< 60 cmh2o or fvc \< 50% of theoretical. 3. stable disease. 4. airway access through nasal mask. 5. ability to provide written informed consent. 6. ability to attend the visits exclusion criteria: 1. contraindications for mechanical ventilation: * patient with terminal disease or vegetative state * lack of motivation of the patient * lack of family or social support * patients clinically unstable * agitation or lack of co-operation * depression. 2. patients with acute symptoms requiring hospital admission. 3. need for airway access through tracheostomy, face mask or mouth piece. 4. relevant comorbidity (ie. heart failure, diabetes non controlled, infections, malignancies, etc.) leading to difficulties in adaptation to ventilation. 5. use (for 7 days or more) of cns depressors(benzodiazepines, antihistamines h1, tricyclic antidepressants , antiepileptic or antipsychotic drugs ) in the 30-day period prior to inclusion, or expected need for such drugs during the study. 6. lack of understanding of the study procedures.

Keywords: respiratory insufficiency hypercapnic chronic respiratory failure secondary to neuromuscular diseases or alterations of thoracic cage
pharmacokinetic study of abt-126 in stable subjects with schizophrenia

Conditions: Schizophrenia

Summary: a study to investigate the process by which abt-126 is absorbed, distributed, metabolized and eliminated by the body of stable schizophrenic volunteers receiving treatment with an atypical antipsychotic.


Eligibility criteria:
inclusion criteria: * subject has signed informed consent; * current diagnosis of schizophrenia; * clinically stable on the same single second-generation (atypical) antipsychotic for the past 8 weeks; * meets study-specific criteria for positive and negative syndrome scale (panss); * females are not pregnant, not breast-feeding; * females are post-menopausal or surgically sterile or practicing birth control; * males are surgically sterile or agree to be sexually inactive or use barrier method of birth control exclusion criteria: * diagnosis of schizoaffective disorder; * diagnosis with mental retardation; * subject has a substance dependence disorder that has not been in sustained remission for at least 1 year; * acute psychosis hospitalization within past 6 months; * bipolar disorder, manic episode, dementia, obsessive-compulsive disorder, or drug-induced psychosis or current major depressive disorder; * current clozapine treatment; * suicidal ideation or behavior; * bmi of 39 or greater; * relevant drug sensitivity or allergy; * positive hepatitis or hiv test result; positive urine screen for drugs of abuse or alcohol; * recent clinically significant illness/infection or surgery; * recent blood product transfusion, donation or loss of 5 ml/kg of blood;

Keywords: pharmacokinetics
the investigation of thoracic spinal curvature and mobility in subjects with and without neck pain: cut-off points

Conditions: Neck Pain

Summary: the purpose of this study is to investigate the sagittal thoracic spinal curvature and mobility in subjects with and without chronic neck pain, cut-off points and pain relationship


Eligibility criteria:
inclusion criteria: * patients aged between 18 and 65 years with persistent neck pain for more than 3 months * the inclusion criteria for the control group included acceptance to participate in the study, no previous neck pain (lifetime-to-date), no spinal surgery or deformity, and no radiological abnormalities detected exclusion criteria: * prior history of injury or surgery relating to spine, spinal deformity, neurological symptoms or signs, radiological abnormalities indicating cervical radiculopathy or myelopathy, prior history of other spinal disorder such as low back pain, active intervention in the last 3 months including drug therapy or physiotherapy, malignancy, systemic pathology including any rheumatologic disease and osteoporosis